找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Critical Issues in Head and Neck Oncology; Key concepts from th Jan B. Vermorken,Volker Budach,Brian O‘Sullivan Conference proceedings 2017

[復(fù)制鏈接]
樓主: Tyler
21#
發(fā)表于 2025-3-25 04:33:21 | 只看該作者
Pros and Cons of Endoscopic Surgeryvative techniques introduced during the last decades in head and neck surgical oncology. The aim of these technologies is to provide patients with treatments associated with the same outcome in terms of local control compared to traditional surgical techniques or radiation/chemoradiation (RT/CRT), b
22#
發(fā)表于 2025-3-25 09:13:52 | 只看該作者
Comprehensive Overview: Definitive Radiotherapy and Concurrent Chemoradiation in Locally Advanced Heion versus standard fractionation led to a small but significant absolute OS benefit of 3.4 % at 5 years in patients with LAD-HNSCC corresponding to a HR reduction for death of 8 %. Hyperfractionation as a specific subtype of altered fractionation led to a highly significant absolute OS and LRC bene
23#
發(fā)表于 2025-3-25 13:42:26 | 只看該作者
Treatment of Viral-Associated HNC (OPC and NPC)ement is applicable to both..NPC is primarily treated with radiotherapy (RT), because of anatomical location that poses a technical challenge for surgery. IMRT is the technique of choice, particularly for locally advanced disease. Patients with stage I and II NPC are managed with RT-alone, but concu
24#
發(fā)表于 2025-3-25 16:37:40 | 只看該作者
Patient and Treatment Factors in Concurrent ChemoradiotherapyRT) alone. High-dose cisplatin (100 mg/m. on days 1, 22, and 43 during RT) was identified as the most effective regimen. Definitive CCRT with high-dose cisplatin is therefore regarded as the preferred choice for the treatment of locoregionally advanced head and neck squamous cell cancer. However, th
25#
發(fā)表于 2025-3-25 22:03:23 | 只看該作者
Recurrent/Metastatic Head and Neck Cancer: When and How to Irradiateregional vs. distant), availability of salvage options in each institution, and patient performance status. The general philosophy underpinning its management is to generally use a different treatment modality compared to what was employed initially. For cases treated with surgery without radiothera
26#
發(fā)表于 2025-3-26 00:55:02 | 只看該作者
E. Striegnitz,C. von Reibnitz,A. Skowronskyrent backgrounds were involved in this, but also representatives of European Cancer Leagues, the European Cancer Coalition (ECPC), patient groups, the European School of Oncology (ESO), the Roy Castle Lung Cancer Foundation, coworkers of Merck and a journalist. The background and evolution of this initiative is subject of this presentation.
27#
發(fā)表于 2025-3-26 07:26:59 | 只看該作者
28#
發(fā)表于 2025-3-26 09:02:18 | 只看該作者
29#
發(fā)表于 2025-3-26 16:21:22 | 只看該作者
https://doi.org/10.1007/978-3-662-55909-3pretation. Through attendance at tumour boards or multi-disciplinary team meetings, pathologists can also provide interpretation of pathology testing in the clinical context, alongside imaging and other investigations.
30#
發(fā)表于 2025-3-26 19:50:03 | 只看該作者
Der Hintergrund der Compliance,ut with less morbidity and decreased hospitalization time. The value of TLM, TORS, and TES in the management of early-stage lesions is widely recognized, while the debate is still ongoing on their role in the treatment of selected intermediate/advanced tumors.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-15 20:30
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
湟中县| 宁安市| 朝阳市| 乳源| 义乌市| 达州市| 华容县| 章丘市| 中超| 精河县| 漯河市| 河津市| 马鞍山市| 合川市| 三河市| 靖西县| 台北市| 广水市| 玛多县| 建阳市| 双江| 正阳县| 深水埗区| 柘城县| 普宁市| 赞皇县| 垦利县| 裕民县| 方正县| 凤阳县| 甘南县| 新营市| 高阳县| 柳河县| 怀宁县| 肥乡县| 肥西县| 泊头市| 霍邱县| 临沂市| 荔波县|